Research Communication: Real‐World Effectiveness of Budesonide Orodispersible Tablets for Eosinophilic Oesophagitis: The Importance of Patience and Education

Budesonide orodispersible tablets (BOT) have been shown to be efficacious for eosinophilic oesophagitis (EoE) in clinical trials. This study evaluated the real-world effectiveness of BOT in a retrospective cohort of 94 patients across six tertiary centres. 61% of patients achieved histological remission and 39% clinicohistological remission following induction therapy. Adverse events were reported by 16% of patients and 17% were noted to have incorrect technique of administration. BOT was demonstrated to have lower rates of clinicohistological remission in real-world practice than reported in clinical trials, largely due to incorrect technique and cessation due to adverse events.

Authors

Institutions

Publication Details

Journal
Alimentary Pharmacology & Therapeutics
Published
2025-05-14
DOI
https://doi.org/10.1111/apt.70197
Citations
2
Primary Topic
Eosinophilic Esophagitis
Type
article
Field-Weighted Citation Impact
4.01

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Research Communication: Real‐World Effectiveness of Budesonide Orodispersible Tablets for Eosinophilic Oesophagitis: The Importance of Patience and Education

Hamish Philpott, Rebecca Burgell, Catherine Yu, Ayushi Chauhan et al.
2 citations
Alimentary Pharmacology & Therapeutics
Eosinophilic Esophagitis
4.01
article

Research Communication: Real‐World Effectiveness of Budesonide Orodispersible Tablets for Eosinophilic Oesophagitis: The Importance of Patience and Education

Hamish Philpott, Rebecca Burgell, Catherine Yu, Ayushi Chauhan, Varan Perananthan, Sarah Lucas, Nikita Parkash, Mayur Garg, Diana J. Lewis, Chamara Basnayake, Katrina Tan, Mani Suleiman, Gloria Sepe, Sarah Taylor, Emily Barwick
article en
2 citations

Abstract

Budesonide orodispersible tablets (BOT) have been shown to be efficacious for eosinophilic oesophagitis (EoE) in clinical trials. This study evaluated the real-world effectiveness of BOT in a retrospective cohort of 94 patients across six tertiary centres. 61% of patients achieved histological remission and 39% clinicohistological remission following induction therapy. Adverse events were reported by 16% of patients and 17% were noted to have incorrect technique of administration. BOT was demonstrated to have lower rates of clinicohistological remission in real-world practice than reported in clinical trials, largely due to incorrect technique and cessation due to adverse events.

Alimentary Pharmacology & TherapeuticsVol. 62(2)
The Royal Melbourne Hospital (AU), The University of Melbourne (AU), Northern Health (AU), La Trobe University (AU), St Vincent's Hospital Melbourne (AU), Eastern Health (AU), Women's and Children's Health Network (AU), Alfred Health (AU)
University of Melbourne
Quality Education
Openalex Percentile: Top 7%
Eosinophilic Esophagitis
4.01
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.